Artículos de revistas
18f-fluoride Pet/ct Is Highly Effective For Excluding Bone Metastases Even In Patients With Equivocal Bone Scintigraphy
Registro en:
European Journal Of Nuclear Medicine And Molecular Imaging. , v. 39, n. 11, p. 1730 - 1736, 2012.
16197070
10.1007/s00259-012-2195-8
2-s2.0-84868247267
Autor
Bortot D.C.
Amorim B.J.
Oki G.C.
Gapski S.B.
Santos A.O.
Lima M.C.L.
Etchebehere E.C.S.C.
Barboza M.F.
Mengatti J.
Ramos C.D.
Institución
Resumen
Purpose Bone scintigraphy (BS) has been used extensively for many years for the diagnosis of bone metastases despite its low specificity and significant rate of equivocal lesions. 18F-Fluoride PET/CT has been proven to have a high sensitivity and specificity in the detection of malignant bone lesions, but its effectiveness in patients with inconclusive lesions on BS is not well documented. This study evaluated the ability of 18F-fluoride PET/CT to exclude bone metastases in patients with various malignant primary tumours and nonspecific findings on BS. Methods We prospectively studied 42 patients (34-88 years of age, 26 women) with different types of tumour. All patients had BS performed for staging or restaging purposes but with inconclusive findings. All patients underwent 18F-fluoride PET/CT. All abnormalities identified on BS images were visually compared with their appearance on the PET/CT images. Results All the 96 inconclusive lesions found on BS images of the 42 patients were identified on PET/CT images. 18F-Fluoride PET/CT correctly excluded bone metastases in 23 patients (68 lesions). Of 19 patients (28 lesions) classified by PET/CT as having metastases, 3 (5 lesions) were finally classified as free of bone metastases on followup. The sensitivity, specificity, and positive and negative predictive values of 18F-fluoride PET/CT were, respectively, 100 %, 88 %, 84 % and 100 % for the identification of patients with metastases (patient analysis) and 100 %, 82 % and 100 % for the identification of metastatic lesions (lesion analysis). Conclusion The factors that make BS inconclusive do not affect 18F-fluoride PET/CT which shows a high sensitivity and negative predictive value for excluding bone metastases even in patients with inconclusive conventional BS. © Springer-Verlag 2012. 39 11 1730 1736 Nicolini, A., Ferrari, P., Sagripanti, A., Carpi, A., The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy (1999) Br J Cancer, 79 (9-10), pp. 1443-1447. , doi101038/sjbjc6690230 Talbot, J.N., Paycha, F., Balogova, S., Diagnosis of bone metastasis: Recent comparative studies of imaging modalities (2011) Q J Nucl Med Mol Imaging, 55 (4), pp. 374-374 Ndlovu, X., George, R., Ellmann, A., Warwick, J., Should spect-ct replace spect for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? (2010) Nucl Med Commun, 31 (7), pp. 659-656. , doi:10.1097/MNM.0b013e3283399107 Cook, G.J., Fogelman, I., The role of positron emission tomography in skeletal disease (2001) Semin Nucl Med, 31 (1), pp. 50-56 Silberstein, E.B., Saenger, E.L., Tofe, A.J., Alexander Jr., G.W., Park, H.M., Imaging of bone metastases with 99mtc-sn-ehdp (diphosphonate), 18f, and skeletal radiography. A comparison of sensitivity (1973) Radiology, 107 (3), pp. 551-555 Blau, M., Nagler, W., Bender, M.A., Fluorine-18: A new isotope for bone scanning (1962) J Nucl Med, 3, pp. 332-334 Picchio, M., Giovannini, E., Messa, C., The role of pet/computed tomography scan in the management of prostate cancer (2011) Curr Opin Urol, 21 (3), pp. 230-236. , doi:10.1097/MOU.0b013e328344e556 Grant, F.D., Fahey, F.H., Packard, A.B., Davis, R.T., Alavi, A., Treves, S.T., Skeletal pet with 18f-fluoride: Applying new technology to an old tracer (2008) J Nucl Med, 49 (1), pp. 68-67. , doi102967/ jnumed106037200 Blake, G.M., Park-Holohan, S.J., Cook, G.J., Fogelman, I., Quantitative studies of bone with the use of 18f-fluoride and 99mtc-methylene diphosphonate (2001) Semin Nucl Med, 31 (1), pp. 28-24 Li, Y., Schiepers, C., Lake, R., Dadparvar, S., Berenji, G.R., Clinical utility of (18)f-fluoride pet/ct in benign and malignant bone diseases (2012) Bone, 50 (1), pp. 128-123. , doi:10.1016/j.bone.2011.09.053 Schiepers, C., Nuyts, J., Bormans, G., Dequeker, J., Bouillon, R., Mortelmans, L., Fluoride kinetics of the axial skeletonmeasured in vivo with fluorine-18-fluoride pet (1997) J NuclMed, 38 (12), pp. 1970-1976 Fogelman, I., Cook, G., Israel, O., Van Der Wall, H., Positron emission tomography and bone metastases (2005) Semin Nucl Med, 35 (2), pp. 135-134. , doi101053/jsemnuclmed2004.11005 Even-Sapir, E., Metser, U., Flusser, G., Zuriel, L., Kollender, Y., Lerman, H., Assessment of malignant skeletal disease: Initial experience with 18f-fluoride pet/ct and comparison between 18ffluoride pet and 18f-fluoride pet/ct (2004) J Nucl Med, 45 (2), pp. 272-278 Withofs, N., Grayet, B., Tancredi, T., Rorive, A., Mella, C., Giacomelli, F., 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers (2011) Nucl Med Commun, 32 (3), pp. 168-167. , doi:10.1097/MNM.0b013e3283412ef5 Yen, R.F., Chen, C.Y., Cheng, M.F., Wu, Y.W., Shiau, Y.C., Wu, K., The diagnostic and prognostic effectiveness of f-18 sodium fluoride pet-ct in detecting bone metastases for hepatocellular carcinoma patients (2010) Nucl Med Commun, 31 (7), pp. 637-634. , doi:10.1097/ MNM.0b013e3283399120 Mattsson, S., Soderberg, M., Radiation dose management in ct spectct and petct techniques (2011) Radiat Prot Dosim, 147 (1-2), pp. 13-12. , doi:10.1093/rpd/ncr261 Rodriguez-Vigil, B., Gomez-Leon, N., Pinilla, I., Hernandez-Maraver, D., Coya, J., Martin-Curto, L., Pet/ct in lymphoma: Prospective study of enhanced full-dose pet/ct versus unenhanced lowdose pet/ct (2006) J Nucl Med, 47 (10), pp. 1643-1648 Pfluger, T., Melzer, H.I., Schneider, V., La Fougere, C., Coppenrath, E., Berking, C., Pet/ct in malignant melanoma: Contrast-enhanced ct versus plain low-dose ct (2011) Eur J NuclMedMol Imaging, 38 (5), pp. 822-823. , doi:101007/s00259-822-31 doi:101007/s00010